Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

NCT06830850 is registered in ClinicalTrials.gov with Atridia Pty Ltd. as lead sponsor.

NCT NCT06830850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06830850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
Lead sponsor
Atridia Pty Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 15, 2025
Completion date
March 15, 2027
Enrollment
25 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer